BUZZ - TriSalus shares surge after FDA approves liver treatment device
路透社2026/09/23 13:53Latest Developments
September 23 - ** Cancer treatment company TriSalus (TLSI.O) shares rose 7.5% to $5.3
** The company (link)'s Trinav Advance device received FDA approval, further expanding its portfolio of liver-targeted therapy products
** The company plans to launch the device on a small scale in the coming weeks
** Five brokers rate the stock as "Buy"; the median price target is $9 — data compiled by LSEG
** Including the day's movement, the stock is down 29.4% so far this year
(To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain mistakes or lack required context, Reuters does not guarantee the accuracy of the automated translation and provides it solely for reader convenience. Reuters accepts no responsibility for any damage or loss caused by the use of automated translation services.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SpaceX President Cashes Out $52 Million Before Monday's Starship Launch
PUMP defends 50-day MA – Is Pump.fun’s bullish trend still intact?
Saylor outlines ‘bill of digital rights’ to help build prosperity in future economy
Crypto prices
More
